Guangzhou Baiyunshan Pharmaceutical Holdings (874) Earnings: FY Net Income Hits 2.84B Yuan with Final Dividend of 40 RMB Cents

A look at Guangzhou Baiyunshan Pharmaceutical Holdings Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Guangzhou Baiyunshan Pharmaceutical Holdings has received positive Smart Scores across several key factors, with top marks for both Value and Dividend prospects. This indicates a strong performance in terms of financial health and potential returns to shareholders. Additionally, the company scores well in Growth, showing promise for future expansion and development. While Resilience and Momentum scores are slightly lower, the overall outlook for Guangzhou Baiyunshan Pharmaceutical Holdings appears favorable, reflecting its position as a manufacturer and distributor of Chinese patent medicine, as well as Western and Chinese pharmaceutical products and medical apparatus.

With a solid foundation in Value and Dividend potential, Guangzhou Baiyunshan Pharmaceutical Holdings is poised for long-term growth and stability. The positive Growth score points towards opportunities for the company to further expand its market presence and offerings. Although Resilience and Momentum scores are not as high, the company’s core focus on Chinese patent medicine manufacturing and pharmaceutical distribution positions it well in the industry. In summary, Guangzhou Baiyunshan Pharmaceutical Holdings demonstrates strength in key aspects, suggesting a promising outlook for investors seeking a well-rounded pharmaceutical player with solid value and growth prospects.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma